Samsung Bioepis/Biogen biosimilar of Remicade launched in UK

8 September 2016

Flixabi, a biosimilar version of US health care giant Johnson & Johnson’s (NYSE: JNJ) inflammatory diseases drug Remicade (infliximab), has been launched in the UK.

This biosimilar, to treat adults with conditions including Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, and psoriasis, has been developed by Samsung Bioepis, a joint venture involving Korean conglomerate Samsung and US biotech major Biogen (Nasdaq: BIIB).

It is being marketed in Europe by Biogen, where Flixabi gained marketing authorization in May, following on from the European Commission approval earlier in the year for Benepali, another anti-TNF biosimilar developed by the venture which references the big-selling product Enbrel (etanercept).

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK